Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 1/20 | 0.38 |
| ▸ | DRD1 | P21728 | 1/20 | 0.38 |
| ▸ | DRD4 | P21917 | 1/20 | 0.38 |
| ▸ | DRD5 | P21918 | 1/20 | 0.38 |
| ▸ | MGLL | Q99685 | 1/20 | 0.36 |
| ▸ | ACLY | P53396 | 1/20 | 0.36 |
| ▸ | SLC9A3 | P48764 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL978114 | 1.00 | DRD2 (0.38) | DRD2DRD1DRD4DRD5MGLL | |
| SCHEMBL980784 | 0.87 | SLC9A3 (0.48) | DRD2DRD1DRD4DRD5ACLY | |
| SCHEMBL980783 | 0.87 | SLC9A3 (0.48) | DRD2DRD1DRD4DRD5ACLY | |
| Hydrochloric Acid SCHEMBL978211 | 0.86 | SLC9A3 (0.48) | DRD2DRD1DRD4DRD5ACLY | |
| Hydrochloric Acid SCHEMBL978210 | 0.86 | SLC9A3 (0.48) | DRD2DRD1DRD4DRD5ACLY | |
| SCHEMBL978847 | 0.85 | SLC9A3 (0.38) | SLC9A3 | |
| SCHEMBL978845 | 0.85 | SLC9A3 (0.38) | SLC9A3 | |
| SCHEMBL979150 | 0.85 | SLC9A3 (0.38) | SLC9A3 | |
| SCHEMBL978344 | 0.83 | SLC9A3 (0.35) | SLC9A3 | |
| SCHEMBL978342 | 0.83 | SLC9A3 (0.35) | SLC9A3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1838315-B1 | SUBSTITUTED 4-PHENYLTETRAHYDROISOQUINOLINES, METHODS FOR PRODUCING THEM, THEIR USE AS DRUG, AND DRUG CONTAINING THEM | SANOFI SA (FR) | 2014-03-12 | — | — | EP | claimed |
| US-7868003-B2 | Substituted 4-phenyltetrahydroisoquinolines, pharmaceutical compositions comprising them and therapeutic methods for their use | SANOFI-AVENTIS (FR) | 2011-01-11 | — | — | US | claimed |
| US-20080058328-A1 | SUBSTITUTED 4-PHENYLTETRAHYDROISOQUINOLINES, PHARMACEUITCAL COMPOSITIONS COMPRISING THEM AND THERAPEUTIC METHODS FOR THEIR USE | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2008-03-06 | — | — | US | claimed |
| EP-1838315-B1 | SUBSTITUTED 4-PHENYLTETRAHYDROISOQUINOLINES, METHODS FOR PRODUCING THEM, THEIR USE AS DRUG, AND DRUG CONTAINING THEM | SANOFI SA (FR) | 2014-03-12 | — | — | EP | disclosed |
| EP-1838315-B1 | SUBSTITUTED 4-PHENYLTETRAHYDROISOQUINOLINES, METHODS FOR PRODUCING THEM, THEIR USE AS DRUG, AND DRUG CONTAINING THEM | SANOFI SA (FR) | 2014-03-12 | — | — | EP | disclosed |
| US-7868003-B2 | Substituted 4-phenyltetrahydroisoquinolines, pharmaceutical compositions comprising them and therapeutic methods for their use | SANOFI-AVENTIS (FR) | 2011-01-11 | — | — | US | disclosed |
| US-7868003-B2 | Substituted 4-phenyltetrahydroisoquinolines, pharmaceutical compositions comprising them and therapeutic methods for their use | SANOFI-AVENTIS (FR) | 2011-01-11 | — | — | US | disclosed |
| US-7868003-B2 | Substituted 4-phenyltetrahydroisoquinolines, pharmaceutical compositions comprising them and therapeutic methods for their use | SANOFI-AVENTIS (FR) | 2011-01-11 | — | — | US | disclosed |
| US-20080058328-A1 | SUBSTITUTED 4-PHENYLTETRAHYDROISOQUINOLINES, PHARMACEUITCAL COMPOSITIONS COMPRISING THEM AND THERAPEUTIC METHODS FOR THEIR USE | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2008-03-06 | — | — | US | disclosed |
| US-20080058328-A1 | SUBSTITUTED 4-PHENYLTETRAHYDROISOQUINOLINES, PHARMACEUITCAL COMPOSITIONS COMPRISING THEM AND THERAPEUTIC METHODS FOR THEIR USE | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2008-03-06 | — | — | US | disclosed |
| US-20080058328-A1 | SUBSTITUTED 4-PHENYLTETRAHYDROISOQUINOLINES, PHARMACEUITCAL COMPOSITIONS COMPRISING THEM AND THERAPEUTIC METHODS FOR THEIR USE | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2008-03-06 | — | — | US | disclosed |
| EP-1838315-A1 | SUBSTITUTED 4-PHENYLTETRAHYDROISOQUINOLINES, METHODS FOR PRODUCING THEM, THEIR USE AS DRUG, AND DRUG CONTAINING THEM | sanofi-aventis (FR) | 2007-10-03 | — | — | EP | disclosed |
| WO-2006074813-A1 | SUBSTITUTED 4-PHENYLTETRAHYDROISOQUINOLINES, METHODS FOR PRODUCING THEM, THEIR USE AS DRUG, AND DRUG CONTAINING THEM | SANOFI-AVENTIS (DE) | 2006-07-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080058328-A1 | SUBSTITUTED 4-PHENYLTETRAHYDROISOQUINOLINES, PHARMACEUITCAL COMPOSITIONS COMPRISING THEM AND THERAPEUTIC METHODS FOR THEIR USE | REN, MTNR1B, MTNR1A | DRD2 463/4885DRD1 481/4885DRD4 388/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.